Jazz Pharmaceuticals Expects $1.08B Net Proceeds from Convertible Offering
JAZZ has more than doubled off its 52-week low of $122.5 on elevated volume (1.8× avg).
Summary
Jazz Pharmaceuticals disclosed expected net proceeds of $1.08 billion from its upsized convertible offering, rising to $1.23 billion if the underwriters' option is exercised in full. The company had previously priced the offering at $1.1 billion, so this provides a concrete net figure after fees. The capital raise follows the $820 million Actio Biosciences acquisition and supports the share buyback announced alongside the offering. The company also agreed to a concurrent $225.0 million share repurchase from note purchasers in privately negotiated transactions, which will reduce the remaining amount under its share repurchase program. The closing of the notes is not contingent upon the closing of the concurrent share repurchases. The offering is dilutive but the stock is trading near its 52-week high, suggesting investor demand for the convertible.
At the time of this announcement, JAZZ was trading at $254.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.9B. The 52-week trading range was $122.50 to $266.38. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.